Cal - tend to agree for all the reasons you stated! Curious that Hikma throws out a projection that matches AMRN 2020 guidance. And, AMRN’s includes CV indication. How could Hikma throw out the same revenue projection when supposedly only going after TG > 500 market and to boot, wouldn’t they undercut price?